Clinical Trials Logo

Clinical Trial Summary

PROMPT (PONV Rescue Outcomes after AMisulPride Treatment) is an observational Phase IV study designed to evaluate real-world evidence in relation to the care continuum of Post Operative Nausea and Vomiting (PONV), as well as the effectiveness and safety of common pharmacologic rescue treatment regimens compared to IV amisulpride. There will be no predefined hypothesis regarding the magnitude of efficacy or safety of various treatment regimens from the cohorts observed. We are not proposing to directly recruit patients into this study.


Clinical Trial Description

Deidentified Electronic Health Record (EHR) information related to treatment of Post Operative Nausea and Vomiting (PONV) will be collected from academic and community hospitals throughout the United States. Deidentified EHRs for patients receiving treatment for PONV will be harvested in two cohorts: Cohort 1, Rescue treatment according to the standard of care (SOC) at each study site prior to the introduction of IV amisulpride into clinical practice Cohort 2, Rescue treatment IV amisulpride. There is no planned investigational agent, prescribed treatment regimen, or mandated intervention, and treating clinicians will determine therapy for PONV according to clinical judgment. The projected inclusion over the course of this observational study is to enroll a total of 20,000+ patient EHRs evenly divided among those that received SOC and amisulpride treatment. Effectiveness and safety outcomes will be analyzed using standard statistical methods for observational studies. Comparison of deidentified patient EHRs in Cohort 1 and Cohort 2, including response rates, will be compiled and analyzed by an independent medical data analytics company. In regard to a Quality Assurance (QA) Plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing, ArborMetrix performs QA as part of regular business. QA involves both automation testing and manual testing strategies including Failure Mode and Effects Analysis (FMEA), bounds testing and exploratory testing. Monitoring and auditing is done in line with their continued work toward HITRUST Compliance. Regarding data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry, data validation is built into the registry configuration based on predefined rules as part of the data analytics and measures development. When receiving data in a batch, legal values, legal relationships, primary keys, constraints, duplicates, range, format, length, data type, parent-child relationship, variable name are all checked at both import and staging. The analytic process checks naming, ticket #, unit test (Statistical Analysis System (SAS), Structure Query Language (SQL)), integration, rules, range, consistency, outliers, missing and distribution. As part of the Risk and Reliability (RR) Adjustment, ArborMetrix checks missing, unique values, Observed to Expected (OE) ratio, C-stats, R squared and adjusted R squared. Report validation in the UI (User Interface), which in this case means the registry platform, compares reporting dictionary to analytic definition. Regarding source data verification and assessing the accuracy, completeness, or representativeness of registry data, data for PROMPT is being pulled directly from the EMR system (i.e., external data sources) into the registry. No source data verification will be conducted. Regarding Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management - there is no patient recruitment for PROMPT. It is an observational study. Information on data collection/management/analysis is answered in other questions. The change management system involves a Change Management Board, Change Management Request form outlining event spurring the change, requested date/time, engineers assigned, devices and/or systems being changed, a description of the change including technical details, impact, risk validation method and backout plan. The Request is peer reviewed and approved by leadership and technical personnel prior to implementation. Plan for missing data to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results - As part of the data integration process, if variables necessary to meet measure criteria are deemed not available, Acacia will determine the next steps (i.e., remove measure, change measure criteria, etc.). ;


Study Design


Related Conditions & MeSH terms

  • Nausea
  • Nausea and Vomiting, Postoperative
  • Postoperative Nausea and Vomiting
  • Vomiting

NCT number NCT04954365
Study type Observational [Patient Registry]
Source Acacia Pharma Ltd
Contact
Status Withdrawn
Phase
Start date November 1, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT01217190 - Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets Phase 1/Phase 2
Recruiting NCT06302673 - The Role Of Laserpuncture For Prevention Of Nausea And Vomiting Post Strabismus Surgery With General Anesthesia In Adult Patients N/A
Recruiting NCT04563494 - The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain Phase 4
Completed NCT00108095 - A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting Phase 2
Not yet recruiting NCT05426278 - The Effect Of Intraoperative Forced Air Warmer Use, On Postoperative Nausea And Vomiting N/A
Not yet recruiting NCT06356623 - A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
Withdrawn NCT05016076 - Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial N/A
Not yet recruiting NCT04899817 - Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy Phase 4
Recruiting NCT05875077 - Propofol Versus Dexmedetomidine on the Incidence of Postoperative Nausea and Vomiting N/A
Completed NCT03338400 - Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role? Phase 2
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Not yet recruiting NCT05692245 - Dexamethasone vs Ondansetron After Cesarean Delivery Phase 4
Completed NCT00334152 - Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women Phase 3
Completed NCT00326248 - Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women Phase 3
Recruiting NCT03586817 - PALONOSETRON X FOSAPREPITANT IN PONV Phase 4
Not yet recruiting NCT06357234 - Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Phase 2
Completed NCT03045133 - QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Phase 4
Recruiting NCT05474001 - Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia N/A
Enrolling by invitation NCT05439798 - Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting Phase 3
Completed NCT03809923 - Dexmedetomidine Combined With Lidocaine Infusion Affect PONV N/A